TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20 to 70 years~* Patients who were diagnosed with early-stage HCC, defined by modified UICC stage 1 or 2~* Patients with treatment-naive and recurrent HCC who have received treatment and achieved complete response at the time of screening~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Patients with insulin resistance (HOMA-IR \>=2.2)~Exclusion Criteria:~* Child Pugh class B or C~* Alcohol intake \>20g/day~* History of decompensation~* Severe medical comorbidities (ischemic heart disease, 3rd degree atrioventricular block, chronic obstructive pulmonary disease, severe hypertension (blood pressure \> 200/120 mmHg) or psychiatric illnesses which limit ability to exercise safely~* Who takes insulin sensitizer (sulfonylurea, biguanide, thiazolidinedione, glucagon-like peptide-1 agonist, dipeptidyl peptidase-4 inhibitor) or uses insulin~* Uncontrolled diabetes mellitus (Hemoglobin A1c \>10%)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Standard care (Type: NO_INTERVENTION): Hepatocellular carcinoma (HCC) patients with insulin resistance who underwent hepatic resection or radiofrequency ablation (RFA) will be enrolled. Patients included in the control arm will receive a booklet including information about physical activity recommendations and practice (education). After 12 weeks, they will also be provided mobile application and wearable device and perform exercise for 12 weeks.
- Mobile health (Type: ACTIVE_COMPARATOR): HCC patients with insulin resistance who underwent hepatic resection or RFA will be enrolled. Patients included in the intervention arm will receive both booklet and mobile health program. They will perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening) for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months - 21 years~* SRNS, defined as failure to achieve remission in proteinuria after 4-6 weeks of daily steroid therapy in accord with ISKDC guidelines~* GFR \> 30 ml/min/1.73 m\^2~* Renal disease diagnosed based on kidney biopsy~Exclusion Criteria:~* Secondary FSGS~* Prior renal transplantation~* Congenital extra-renal abnormalities~* Significant structural cardiac abnormalities~* pulmonary, hematologic, malignancy, or immune-related disease~* inability to maintain adequate follow-up

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Focal Segmental Glomerulosclerosis (Type: None): None
- Non-Focal Segmental Glomerulosclerosis (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Duke Scleroderma Clinic Patient Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of systemic sclerosis or Scleroderma as identified by the 2013 American College of Rheumatology classification criteria~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed lymphoblastic lymphoma (LBL)~  * Stage I-IV disease~ * T-cell LBL, precursor B-cell LBL, or LBL with an unknown immunophenotype~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No known HIV or AIDS infection~* No severe immunodeficiency~* No other prior malignancy~* No prior disease that would preclude treatment with chemotherapy~PRIOR CONCURRENT THERAPY:~* More than 2 months since prior systemic corticosteroids for a duration of \> 8 days~* No prior chemotherapy~* No prior radiotherapy~* No prior organ transplant~* No trimethoprim-sulfamethoxazole 6 days before or during methotrexate therapy~* No concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise in Pediatric Autologous Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* autologous SCT at Alberta Children's Hospital (ACH) for malignancy~* age 5 to 18 years of age~* will be receiving myeloablative conditioning regimen~* no evidence of cardiac or pulmonary failure associated with treatment (SF≥28%, EF ≥ 50%)~* no functional nor cognitive limitation that would prohibit performance of the home-based training~* approval by treating oncologist for participants~* a parent or legal guardian must sign the consent form and~* children should express verbal assent to participate.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Exercise (EX) (Type: EXPERIMENTAL): This group will perform two phases of an EX program.
- Standard Care (Type: ACTIVE_COMPARATOR): This group will follow the standard care without any EX prescription.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of advanced hepatobiliary carcinoma not amenable to conventional surgery~  * Gall bladder carcinoma~ * Cholangiocarcinoma~ * Carcinoma of the ampulla~ * Hepatocellular carcinoma (eligible for cohort II only)~* Measurable disease~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* At least 12 weeks~Hematopoietic:~* WBC at least 3,000/mm\^3~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin greater than 10 g/dL~Hepatic:~* Bilirubin less than 3 mg/dL~  * Cohort I (closed to accrual as of 11/1/03)~    * Bilirubin no greater than 1.5 mg/dL~   * AST no greater than 2.5 times upper limit of normal (ULN)~ * Cohort II~    * Bilirubin greater than 1.5 mg/dL and less than 3 mg/dL OR~   * Bilirubin no greater 1.5 mg/dL AND AST greater than 2.5 times ULN~Renal:~* Creatinine normal OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No New York Heart Association class III or IV heart disease~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for cholangiocarcinoma or hepatobiliary carcinoma~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No concurrent combination antiviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Narcotic-Induced Nausea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient in Christian Care Emergency Department~2. Require intravenous narcotics for painful condition~3. ≥18 years of age~4. Able to visually rate amount of pain and nausea~Exclusion Criteria:~1. Hypersensitivity to promethazine or opioids~2. Patient requesting anti-emetic at enrollment~3. Narcotic administration in last 6 hours~4. Pregnancy or currently breast-feeding~5. Known seizure disorder~6. Medical Instability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
- 2 (Type: ACTIVE_COMPARATOR): Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for laparoscopic procedure~* Had a preoperative CT image that includes the liver~Exclusion Criteria:~* Severe cirrhosis of the liver~* Kidney failure or dialysis~* Unable to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults living in Riyadh area with impaired fasting glucose or/and impaired glucose tolerance (prediabetics) and total 25 OH vitamin D level between 10-30 nmol/l~* Who consume no more than one serving of milk/day~* Do not take vitamin supplement~* Habitually have less than 10 hour of sun exposure per week~* Don't suffer from granulomatus conditions, liver disease, kidney disease, or diabetes~* Don't take anticonvulsants, barbiturates, steroids, or antidiabetic medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Vitamin D3 5000 IU daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who will be undergoing latissimus dorsi donor flap harvest reconstruction and evaluated by the Department of Plastic and Reconstructive Surgery at Oregon Health and Science University (OHSU)~* These patients will be undergoing reconstructive surgery for a mastectomy/wide local excision of breast cancer defect or other soft tissue defect resulting from trauma, infection, undesirable surgical outcome, oncologic resection, etc.~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients who will not qualify for latissimus dorsi donor flap reconstruction based on anatomical limitations specific the subjects respectively; to be evaluated by the plastic surgeon~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to fibrin glue sealant~* Patients with evidence of hematological disorders resulting in deficient coagulation whereby sharp dissection would result in undesirable bleeding otherwise performed more safely with electrosurgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (fibrin sealant) (Type: EXPERIMENTAL): Patients undergo sharp dissection technique with fibrin sealant closure.
- Arm II (standard electrocoagulation) (Type: ACTIVE_COMPARATOR): Patients undergo standard electrocoagulation dissection technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incontinence Ring on Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of urinary stress urinary incontinence (i.e. urinary leakage associated with increased intra-abdominal pressure/cough) (if mixed incontinence the urinary stress urinary incontinence symptoms must predominate)~* Urodynamic Stress urinary incontinence confirmed by urodynamic studies (i.e. urinary leakage associated with increased intra-abdominal pressure/cough in the absence of detrusor overactivity)~* Ability to understand spoken and written English~Exclusion Criteria:~* Severe pelvic organ prolapse (\> or = stage 3 on the Pelvic Organ Prolapse Quantification System - POP-Q)~* Contraindications to pessary use (including acute vaginal/urinary or pelvic infections, vaginal or cervical lesions or unexplained vaginal bleeding)~* Inability to properly fit the incontinence ring

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Incontinence ring then no intervention (Type: EXPERIMENTAL): Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
- No intervention then incontinence ring (Type: EXPERIMENTAL): Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant is capable of providing written consent.~* 18 years of age or older.~* Patient with a known or suspected FDG-avid malignancy in the torso~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breath-Hold PET/CT image (Type: None): In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 75 years with a suspicious nodule of malignancy (primary lung tumor or metastasis of another solid tumor whose largest diameter is greater than or equal to 8 mm):~* Not associated with endobronchial tumor visible during inspection of tracheobronchial tree with soft bronchoscope~* Located in any part of the lung more than 10mm from the pleura~* For which surgical management (atypical resection, lobectomy, bilobectomy or pneumonectomy) is planned after presentation of the file at a multidisciplinary consultation meeting on thoracic oncology of the Investigating Hospital Center~* Patient able to understand the course of the study and giving informed consent~* Affiliate or beneficiary of a social security scheme~Exclusion Criteria:~* Threatening cardiac arrhythmias defined by a rhythm disorder dating discovered less than a month ago~* Myocardial infarction less than one month old~* Hypercapnic respiratory decompensation less than one month old~* coagulopathy~* Thrombocytopenia with platelet count \<100,000 / mm3~* Antecedent (ATCD) of significant bleeding during previous bronchoscopy~* ATCD of pulmonary arterial hypertension (PAH) or suspicion of PAH defined by a measurement of systolic pulmonary arterial pressure greater than 50 mmHg on echocardiography (this examination is not systematic but the suspicion of PAH on the thoracic CT scan leads to other cardiac echocardiographic examinations or right heart catheterization in case of inconclusive ultrasound)~* ATCD of pneumonectomy~* Giant bubble\> 5cm located near the nodule or the tunneling path~* Inability to stop anticoagulant or antiplatelet therapy before the procedure (taking acetylsalicylic acid at any dose is allowed)~* Pregnant or lactating woman~* ATCD for thoracic radiotherapy on the nodule side~* Patient under tutorship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Archimedes procedure (Type: EXPERIMENTAL): All included patients will receive anesthesia consultation, biological assessment and chest CT scan in thin sections. A surgical treatment will always be planned after presentation of the file in a meeting of multidisciplinary consultation of thoracic oncology. The Archimedes® procedure will be performed during a bronchoscopy under general anesthesia. Immediate monitoring consisted in a chest x-ray 1hour after the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: i-Sleep: Internet-based Treatment for Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Being 18 years of age or older~* Meet ICSD-3 diagnostic criteria for Insomnia as confirmed by the telephone administered Interview~* Acess to the Internet~* Written informed consent~Exclusion Criteria:~* Physiological Insomnia~* Serious psychiatric co-morbidity that requires alternative treatment including major depression disorder, anxiety disorder, substance dependence, bipolar affective disorder, psychotic illness~* Epilepsy (seizure disorder)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Multicomponent internet-based self-help (Type: EXPERIMENTAL): Multicomponent internet-based self-help
- Internet-based sleep restriction (Type: EXPERIMENTAL): Internet-based sleep restriction
- Waiting control group (Type: NO_INTERVENTION): Access to internet-based intervention after 8-weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues